Company intelligence / Profile preview
CellAct Pharma GmbH
Dortmund, Nordrhein-Westfalen, Germanycellact.eu ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Phase 2
01
Overview
CellAct Pharma GmbH develops innovative therapeutics targeting high unmet medical needs in oncology and immune-mediated inflammatory diseases. Its lead candidate CAP7.1—a small-molecule prodrug of etoposide targeting topoisomerase II—entered Phase I clinical trials for advanced cancers after showing promising preclinical efficacy and tolerability in pediatric neuroblastoma patients. The company also develops monoclonal antibodies against lymphocyte surface molecules to treat cancer and inflammation. As of the latest reports, the pipeline includes both active and discontinued programs across oncology and immunology indications.
- Therapeutic areas
- OncologyImmunologyRheumatology
- Modalities
- Small molecules (e.g., CAP7.1, a prodrug of etoposide)Monoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →03
Partnerships
Licensed key compound from Charité University Hospital Berlinreceived grant funding from German Ministry for Education & Science.
Beyond the preview
Go deeper on CellAct Pharma GmbH.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CellAct Pharma GmbH.